27 completed, 4 terminated, 2 unknown, 1 withdrawn. 34 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 34 | Completed 27, Terminated 4, Unknown 2, Withdrawn 1 |
| Phase 2 | 11 | Completed 5, Terminated 3, Unknown 2, Withdrawn 1 |
Follow Interferon alpha-2: new trials by email Literature Review of Interferon alpha-2 trials Research Report on Interferon alpha-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Celecoxib - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 5 | 2024-02-16 | 2026-08-31 |
| Interferon Alpha Therapy for Cervical CINI and HPV Infection gel Interferon arm, gel Interferon and interferon suppository arm - Cervical Dysplasia, HPV Infection | Phase 1 | Completed | Mongolian National University of Medical Sciences | 60 | 2023-11-07 | 2025-04-03 |
| Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 4 | 2020-11-17 | 2026-01-13 |
| Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer Celecoxib, Cyclophosphamide, Doxorubicin - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2019-12-06 | 2023-09-11 |
| Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer Tumor Infiltrating Lymphocytes (TIL), Interferon Alfa 2A, Carboplatin - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Unknown | Leiden University Medical Center | 12 | 2018-08-01 | 2021-04-01 |
| Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Multiple drug microinjection, CIVO device - Soft Tissue Sarcoma Adult | Phase 1 | Completed | Presage Biosciences | 23 | 2016-12-15 | 2021-09-24 |
| Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis BMS-986202, Placebo, Interferon alpha-2a recombinant - Psoriasis | Phase 1 | Completed | Bristol-Myers Squibb | 357 | 2016-05-18 | 2017-08-03 |
| Interferon-α After DLI for the Prevention of Relapse Interferon Alfa-2b - Leukemia | Phase 1 / Phase 2 | Unknown | Peking University People's Hospital | 42 | 2015-12-01 | 2016-09-29 |
| Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis BMS-986165, Interferon alpha-2a recombinant, Famotidine - Healthy Subjects | Phase 1 | Completed | Bristol-Myers Squibb | 140 | 2015-10-01 | 2016-12-28 |
| Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b Pembrolizumab and high dose interferon alfa-2b (HDI) - Melanoma | Phase 1 | Completed | Yana Najjar | 31 | 2015-03-06 | 2021-02-24 |
| A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors Atezolizumab, Bevacizumab, Interferon alfa-2b - Solid Cancers | Phase 1 | Completed | Hoffmann-La Roche | 158 | 2014-08-18 | 2020-05-12 |
| αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies DC vaccine, Celecoxib, Interferon Alfa-2b - Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma | Phase 1 / Phase 2 | Completed | David Bartlett | 64 | 2014-07-01 | 2020-07-20 |
| Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients Human Serum ALbumin/interferon alpha2a, Pegasys - Chronic Hepatitis B | Phase 1 / Phase 2 | Completed | Beijing Bio-Fortune Ltd. | 32 | 2013-11-01 | 2014-11-17 |
| Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma High-dose Interferon alfa-2b, Vemurafenib - Melanoma | Phase 1 | Completed | John Kirkwood | 7 | 2013-10-01 | 2018-04-03 |
| Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C., Peginterferon 180 mcg single dose S.C. - Healthy Volunteers | Phase 1 | Completed | Beijing Bio-Fortune Ltd. | 34 | 2013-04-01 | 2014-11-17 |
| IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma Ipilimumab, Temozolomide, Cisplatin - Melanoma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 19 | 2013-02-01 | 2017-05-31 |
| Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2) - Colorectal Cancer, Colorectal Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 15 | 2012-10-01 | 2023-10-27 |
| Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer Interferon Alfa-2b, p53 SLP - Recurrent Ovarian Cancer | Phase 1 / Phase 2 | Completed | Leiden University Medical Center | 15 | 2011-08-01 | 2014-01-07 |
| Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma Pazopanib + interferon alpha 2A - Advanced Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | Spanish Oncology Genito-Urinary Group | 53 | 2011-07-11 | 2022-03-10 |
| Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia Influenza Vaccine Trivalent Inactivated (TIV), Pegylated interferon (PEGrIFN-α, Pegasys), Interferon (IFNα, Roferon-A) - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2011-04-01 | 2012-08-03 |
Showing 20 of 34. Sign in to see all of them.
HIV Infections (8) · Acquired Immunodeficiency Syndrome (5) · Melanoma (5) · AIDS-Related Complex (3) · Hepatitis C (3) · Sarcoma, Kaposi (3) · Leukemia (2) · Neoplasm Metastasis (2) · Recurrence (2) · Triple Negative Breast Neoplasms (2) · AIDS-Related Opportunistic Infections (1) · Anus Neoplasms (1) · Breast Carcinoma In Situ (1) · Breast Neoplasms (1) · Coinfection (1)
National Institute of Allergy and Infectious Diseases (NIAID) (8) · M.D. Anderson Cancer Center (4) · Roswell Park Cancer Institute (4) · Beijing Bio-Fortune Ltd. (2) · Bristol-Myers Squibb (2) · Leiden University Medical Center (2) · David Bartlett (1) · Hoffmann-La Roche (1) · Institut Paoli-Calmettes (1) · John Kirkwood (1) · Mongolian National University of Medical Sciences (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1) · Peking University People's Hospital (1) · Presage Biosciences (1)
United States (22) · China (3) · Netherlands (3) · Australia (2) · Puerto Rico (2) · France (1) · Mongolia (1) · Spain (1)
Amar Safdar, MD (1) · Amer H Zureikat, MD (1) · Ashish M. Kamat, MD (1) · Batsuren Choijamts, Ph.D (1) · Critchlow C (1) · D Mildvan (1) · David L Bartlett, MD (1) · Diaz C (1) · Ellis Levine, MD (1) · Eyster ME (1) · Fischl MA (1)
PMID 24316557, PMID 32299817, PMID 36325947
2014 (1), P01CA132714 (1), P01CA234212 (1), P30CA016056 (1), P30CA016058 (1), P30CA016672 (1), P50CA091846 (1), R01AI049141 (1), U01CA076576 (1), UL1TR001412 (1)